CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 16 enrolled
Drug / intervention
spironolactonedrug
Likely dose
spironolactone 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00574119
NCT00574119Phase 4Completed
CompareCT.gov

Effect of Aldosterone on Energy Starvation in Heart Failure

Vanderbilt University·interventional·Posted Dec 17, 2007·Updated Jun 18, 2019

In Brief

A Phase 4 clinical trial evaluating spironolactone for Heart Failure and Nonischemic Dilated Cardiomyopathy. Completed, enrolled 16 participants across 1 site.

Detailed Summary

We plan to study the concept of "energy starvation" in heart failure by evaluation of patients with nonischemic dilated cardiomyopathy (NIDCM) (heart failure with reduced heart pump function due to causes other than heart attack). We will use a combination of positron emission tomography and magnetic resonance imaging to study metabolism, anatomy, function, blood flow and efficiency, before and after 6 months' treatment with the drug spironolactone which blocks the deleterious effects of the hormone aldosterone on the myocardium (heart muscle).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure, Nonischemic Dilated Cardiomyopathy
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 17, 2007
Enrollment StartDec 1, 2007
Primary CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 18.5 years ago

Interventions

spironolactonedrug

spironolactone 50 mg daily for 6 months